Anavex Life Sciences Corp. (NASDAQ:AVXL) is one of the 10 most shorted penny stocks to buy. More than 500% upside potential ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) on Saturday announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration on clinical decline, ...

View Anavex Life Sciences Corp. AVXL stock quote prices, financial information, real-time forecasts, and company news from CNN.

Anavex is set to release its financial results for the second fiscal quarter on May 13, 2025, providing transparency to shareholders and stakeholders. The conference call scheduled after the results ...

Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesineConvergence of impaired ...

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative ...

Anavex Life Sciences ( (AVXL)) has issued an update. On March 25, 2026, Anavex Life Sciences withdrew its application for EU marketing authorization of its lead candidate blarcamesine as an add-on ...

Anavex Life Sciences Corp. has announced its second-quarter financial results for fiscal 2025, highlighting its focus on developing treatments for Alzheimer's disease, schizophrenia, and other CNS ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) reported a peer-reviewed publication in the journal Neuroscience Letters on Wednesday. The study shows that a pre-treatment with blarcamesine prevented Amyloid ...

・The company now intends to request a re-examination of the opinion which would be undertaken by a different set of reviewers that conduct a new examination. ・Anavex submitted an application to the ...

NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson ...

Anavex Life Sciences (NASDAQ:AVXL) is prioritizing upcoming pivotal studies and continued regulatory engagement as it seeks potential pathways to market authorization for its oral central nervous ...